The Correlation Between Immunohistochemistry Findings and Metastasis in Squamous Cell Carcinoma: A Review.
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ metabolism
CD8 Antigens
/ metabolism
Cadherins
/ metabolism
Carcinoma, Squamous Cell
/ immunology
Cyclin D1
/ metabolism
ErbB Receptors
/ metabolism
Humans
Immunocompromised Host
Immunohistochemistry
Membrane Glycoproteins
/ metabolism
Neoplasm Metastasis
Skin Neoplasms
/ immunology
T-Lymphocytes
/ metabolism
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
10
11
2020
medline:
18
8
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer. Only 2% to 5% of SCCs metastasize; however, those do carry a poor prognosis. Immunohistochemistry (IHC) is widely used by pathologists to characterize skin cancers and provide clinically useful information. To evaluate the potential prognostic associations between IHC findings and metastasis in SCC. Searches were conducted in MEDLINE via PubMed for articles published between 1999 and 2019. Search criteria included key words "immunohistochemistry" and "cutaneous squamous cell carcinoma." Six hundred and fifty-three articles were returned and screened, which ultimately left 31 for inclusion in our manuscript. Thirty-one articles analyzed in this review included a discussion of the expression of a particular IHC marker and the associated risk of metastasis and/or clinical utility of IHC markers in SCC, especially metastatic SCC. Markers that had several or more studies supporting clinical utility were E-cadherin, podoplanin, CD8+ T cells, PD-L1, epidermal growth factor receptor, and Cyclin D1. Immunohistochemistry profiling of SCC may be useful in select cases when providing a prognosis remains challenging and in identification of potential therapeutic targets for high-risk or metastatic tumors.
Sections du résumé
BACKGROUND
Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer. Only 2% to 5% of SCCs metastasize; however, those do carry a poor prognosis. Immunohistochemistry (IHC) is widely used by pathologists to characterize skin cancers and provide clinically useful information.
OBJECTIVE
To evaluate the potential prognostic associations between IHC findings and metastasis in SCC.
METHODS
Searches were conducted in MEDLINE via PubMed for articles published between 1999 and 2019. Search criteria included key words "immunohistochemistry" and "cutaneous squamous cell carcinoma." Six hundred and fifty-three articles were returned and screened, which ultimately left 31 for inclusion in our manuscript.
RESULTS
Thirty-one articles analyzed in this review included a discussion of the expression of a particular IHC marker and the associated risk of metastasis and/or clinical utility of IHC markers in SCC, especially metastatic SCC. Markers that had several or more studies supporting clinical utility were E-cadherin, podoplanin, CD8+ T cells, PD-L1, epidermal growth factor receptor, and Cyclin D1.
CONCLUSION
Immunohistochemistry profiling of SCC may be useful in select cases when providing a prognosis remains challenging and in identification of potential therapeutic targets for high-risk or metastatic tumors.
Identifiants
pubmed: 33165065
pii: 00042728-202103000-00001
doi: 10.1097/DSS.0000000000002850
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CCND1 protein, human
0
CD274 protein, human
0
CD8 Antigens
0
Cadherins
0
Membrane Glycoproteins
0
PDPN protein, human
0
Cyclin D1
136601-57-5
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-318Informations de copyright
Copyright © 2020 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Muzic JG, Schmitt AR, Wright AC, Alniemi DT, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in olmsted county, Minnesota, 2000 to 2010. Mayo Clin Proc 2017;92:890–8.
Brantsch KD, Meisner C, Schönfisch B, Trilling B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008;9:713–20.
Moore BA, Weber RS, Prieto V, El-Naggar A, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:1561–7.
Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012;106:811–5.
Belkin D, Carucci JA. Mohs surgery for squamous cell carcinoma. Dermatol Clin 2011;29:161-vii.
Turner SJ, Morgan GJ, Palme CE, Veness MJ. Metastatic cutaneous squamous cell carcinoma of the external ear: a high-risk cutaneous subsite. J Laryngol Otol 2010;124:26–31.
Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013;149:402–10.
Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 2014;150:19–24.
Feinstein S, Higgins S, Ahadiat O, Wysong A. A retrospective cohort study of cutaneous squamous cell carcinoma with lymph node metastasis: risk factors and clinical course. Dermatol Surg 2019;45:772–81.
Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129.
Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cel Biochem 1996;61:514–23.
Bae YK, Choi JE, Kang SH, Lee SJ. Epithelial-mesenchymal transition phenotype is associated with clinicopathological factors that indicate aggressive biological behavior and poor clinical outcomes in invasive breast cancer. J Breast Cancer 2015;18:256–63.
George JT, Jolly MK, Xu S, Somarelli JA, et al. Survival outcomes in cancer patients predicted by a partial EMT gene expression scoring metric. Cancer Res 2017;77:6415–28.
Ling ZQ, Li P, Ge MH, Zhao X, et al. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer. Int J Mol Med 2011;27:625–35.
Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005;11:2156–62.
Marsit CJ, Posner MR, McClean MD, Kelsey KT. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer 2008;113:1566–71.
Toll A, Masferrer E, Hernández-Ruiz ME, Ferrandiz-Pulido C, et al. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. J Dermatol Sci 2013;72:93–102.
Hesse K, Satzger I, Schacht V, Köther B, et al. Characterisation of prognosis and invasion of cutaneous squamous cell carcinoma by podoplanin and E-cadherin expression. Dermatology 2016;232:558–65.
Uribe D, Cardona A, Esposti DD, Cros MP, et al. Antiproliferative effects of epigenetic modifier drugs through E-cadherin up-regulation in liver cancer cell lines. Ann Hepatol 2018;17:444–60.
Ugorski M, Dziegiel P, Suchanski J. Podoplanin - a small glycoprotein with many faces. Am J Cancer Res 2016;6:370–86.
Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost 2011;9:44–55.
Cañueto J, Cardeñoso-Álvarez E, Cosano-Quero A, Santos-Briz Á, et al. The expression of podoplanin is associated with poor outcome in cutaneous squamous cell carcinoma. J Cutan Pathol 2017;44:144–51.
Kreppel M, Krakowezki A, Kreppel B, Drebber U, et al. Podoplanin expression in cutaneous head and neck squamous cell carcinoma—prognostic value and clinicopathologic implications. J Surg Oncol 2013;107:376–83.
Xu M, Wang X, Pan Y, Zhao X, et al. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. BMC Cancer 2019;19:599.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, et al. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010;9:3807–14.
Esparza-López J, Alvarado-Muñoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, et al. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways. BMC Cancer 2019;19:728.
Zhang S, Fujita H, Mitsui H, Yanofsky VR, et al. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS One 2013;8:e62154.
Azzimonti B, Zavattaro E, Provasi M, Vidali M, et al. Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio. Br J Dermatol 2015;172:64–73.
Pagès F, Mlecnik B, Marliot F, Bindea G, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018;391:2128–39.
García-Díez I, Hernández-Ruiz E, Andrades E, Gimeno J, et al. PD-L1 expression is increased in metastasizing squamous cell carcinomas and their metastases. Am J Dermatopathol 2019;41:537. Corrected and republished from: Am J Dermatopathol. 2018;40:647-654.
Kamiya S, Kato J, Kamiya T, Yamashita T, et al. Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma. Asia Pac J Clin Oncol 2020;16:e108–e112.
García-Pedrero JM, Martínez-Camblor P, Diaz-Coto S, Munguia-Calzada P, et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 2017;77:527–33.
Amoils M, Kim J, Lee C, Sunwoo JB, et al. PD-L1 expression and tumor-infiltrating lymphocytes in high-risk and metastatic cutaneous squamous cell carcinoma. Otolaryngol Head Neck Surg 2019;160:93–9.
Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol 2016;43:663–70.
Koppolu V, Rekha Vasigala VK. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther 2018;14:1167–75.
Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 2019;24(Suppl 1):S31–S41.
Migden MR, Rischin D, Schmults CD, Guminski A, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379:341–51.
Ding W, LaPlant BR, Call TG, Parikh SA, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017;129:3419–27.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.
Sharma P, Callahan MK, Bono P, Kim J, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2019;20:e71. Corrected and republished from: Lancet Oncol. 2016;17:1590-1598.
Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3–S8.
Ch'ng S, Low I, Ng D, Brasch J, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008;39:344–9.
Cañueto J, Cardeñoso E, García JL, Santos-Briz Á, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol 2017;176:1279–87.
Shimizu T, Izumi H, Oga A, Furumoto H, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 2001;202:203–6.
Sweeny L, Dean NR, Magnuson JS, Carroll WR, et al. EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 2012;34:681–6.
Kitagawa Y, Ueda M, Ando N, Ozawa S, et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996;2:909–14.
Diedrich U, Lucius J, Baron E, Behnke J, et al. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 1995;242:683–8.
Harris AL, Nicholson S, Sainsbury JR, Farndon J, et al. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989;34:123–31.
Foote MC, McGrath M, Guminski A, Hughes BGM, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014;25:2047–52.
Gold KA, Kies MS, William WN Jr, Johnson FM, et al. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial. Cancer 2018;124:2169–73.
Pirker R, Pereira JR, von Pawel J, Krzakowski M, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33–42.
Ross DA, Nykamp D. Epidermal growth factor receptor inhibitors and skin rash. US Pharm 2014;39:3–6.
Pérez-Soler R, Delord JP, Halpern A, Kelly K, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345–56.
Clark GM, Pérez-Soler R, Siu L, Gordon AS, et al. Rash severity is predictive of increased survival with erlotinib HCl [abstract]. Proc Am Soc Clin Oncol 2003;22:196.
Saltz L, Rubin M, Hochster H, Tchekmeydian NS, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc NCI-AACR-EORTC 2001;559:3766S–3766S.
Saltz L, Kies M, Abbruzzese JL, Azarnia N, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204.
Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405–15.
Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 2002;277:2207–15.
Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl) 2016;94:1313–26.
Huang K, Huang C, Shan K, Chen J, et al. Significance of PC cell-derived growth factor and cyclin D1 expression in cutaneous squamous cell carcinoma. Clin Exp Dermatol 2012;37:411–7.
Mastoraki A, Ioannidis E, Apostolaki A, Patsouris E, et al. PGP 9.5 and cyclin D1 coexpression in cutaneous squamous cell carcinomas. Int J Surg Pathol 2009;17:413–20.
Li YY, Hanna GJ, Laga AC, Haddad RI, et al. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res 2015;21:1447–56.
Cornell L, Wander SA, Visal T, Wagle N, et al. MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance. Cell Rep 2019;26:2667–80.e7.
Geissler EK. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transpl Res 2015;4:1.
Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med 2015;4:1229–39.
Martinez JC, Otley CC, Stasko T, Euvrard S, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003;139:301–6.
Spain L, Higgins R, Gopalakrishnan K, Turajlic S, et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 2016;27:1135–7.
Owonikoko TK, Kumar M, Yang S, Kamphorst AO, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother 2017;66:45–50.
Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016;374:896–8.
Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol 2020;82:1490–500.
Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American joint committee on cancer staging manual, 8th edition vs the brigham and women's hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019;155:819–25.
Suiqing C, Min Z, Lirong C. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 2005;32:354–60.
Liu D, Feng X, Wu X, Li Z, et al. Tumor suppressor in lung cancer 1 (TSLC1), a novel tumor suppressor gene, is implicated in the regulation of proliferation, invasion, cell cycle, apoptosis, and tumorigenicity in cutaneous squamous cell carcinoma. Tumour Biol 2013;34:3773–83.
Wang SJ, Zhang C, You Y, Shi CM. Overexpression of RNA helicase p68 protein in cutaneous squamous cell carcinoma. Clin Exp Dermatol 2012;37:882–8.
Keehn CA, Smoller BR, Morgan MB. Ets-1 immunohistochemical expression in non-melanoma skin carcinoma. J Cutan Pathol 2004;31:8–13.
Munguía-Calzada P, Fernández-Vega I, Martínez-Camblor P, Díaz-Coto S, et al. Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma. Head Neck 2019;41:1290–6.
Kang M, Cho JH, Koo JK, Noh SU, et al. The expression of NMDA receptor 1 correlates with clinicopathological parameters in cutaneous squamous cell carcinoma. Ann Dermatol 2009;21:382–8.
Khandelwal AR, Ma X, Egan P, Kaskas NM, et al. Biomarker and pathologic predictors of cutaneous squamous cell carcinoma aggressiveness. Otolaryngol Head Neck Surg 2016;155:281–8.
Sekulic A, Kim SY, Hostetter G, Savage S, et al. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. Cancer Prev Res (Phila) 2010;3:1277–83.
Hernández-Ruiz E, Toll A, García-Diez I, Andrades E, et al. The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma. Carcinogenesis 2019;40:1052. Corrected and republished from: Carcinogenesis. 2018;39:503-513.
Tanemura A, Nagasawa T, Inui S, Itami S. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 2005;31:423–30.
Santos-Juanes J, Fernández-Vega I, Lorenzo-Herrero S, Sordo-Bahamonde C, et al. Lectin-like transcript 1 (LLT1) expression is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma. Arch Dermatol Res 2019;311:369–76.
Chen MK, Cai MY, Luo RZ, Tian X, et al. Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. Br J Dermatol 2015;172:111–9.
Muchemwa FC, Nakatsura T, Ihn H, Kageshita T. Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell carcinoma. Br J Dermatol 2006;155:582–5.
Lai C, August S, Behar R, Polak M, et al. Characteristics of immunosuppressive regulatory T cells in cutaneous squamous cell carcinomas and role in metastasis. Lancet 2015;385(Suppl 1):S59.